64732-34-9

Usage

Uses

Used in Plasticizer Industry:
4-Methylbenzylsulfonamide is used as a plasticizer for enhancing the flexibility and workability of various polymers and resins. Its properties contribute to the improved performance of these materials in their respective applications.
Used in Pharmaceutical and Agrochemical Synthesis:
4-Methylbenzylsulfonamide serves as a precursor in the synthesis of pharmaceuticals and agrochemicals, playing a crucial role in the development of new drugs and agricultural products.
Used in Lubricant and Coolant Production:
As an additive in the production of lubricants and coolants, 4-Methylbenzylsulfonamide helps improve the thermal stability and performance of these fluids, ensuring efficient operation in various mechanical systems.
Used in Adhesive and Sealant Manufacturing:
4-Methylbenzylsulfonamide is utilized in the manufacturing of adhesives and sealants, where its properties enhance the bonding strength and durability of these products, making them suitable for a wide range of applications.

Upstream product

• 104-82-5 4-Methylbenzyl chloride 
• 51419-59-1 4-methylbenzylsulfonyl chloride 
• 940-63-6 amino[(4-methylbenzyl)thio]methaniminium chloride 
• 3395-88-8 4-methylbenzyl methyl ether 
• 61017-18-3 O-(methylsulfonyl)hydroxylamine 

Downstream Products

• 126423-60-7 N-sulfinyl(p-methylphenyl)methanesulfonamide 
• 1204588-70-4 1-(5-butyryl-3-cyano-6-methylpyridin-2-yl)-N-[(4-methylbenzyl)sulfonyl]piperidine-4-carboxamide 
• 919354-63-5 1-(4-methylcyclohexyl)methanesulfonamide 
• 126423-67-4 N-[(1R,3S,5R,6R,7S,10R)-3,6-Bis-(tert-butyl-dimethyl-silanyloxy)-2,4-dioxa-tricyclo[3.3.1.1^3,7]dec-10-yl]-C-p-tolyl-methanesulfonamide 
• 126423-66-3 (R)-2-[(3aR,4R,6R,7aR)-6-(tert-Butyl-dimethyl-silanyloxy)-2,2-dimethyl-hexahydro-benzo[1,3]dioxol-4-yl]-N-methoxy-N-methyl-2-p-tolylmethanesulfonylamino-acetamide 
• 126423-70-9 Acetic acid (1S,2S)-2-[(3aS,4S,6S,7aS)-6-(tert-butyl-dimethyl-silanyloxy)-2,2-dimethyl-hexahydro-benzo[1,3]dioxol-4-yl]-1-methyl-2-p-tolylmethanesulfonylamino-ethyl ester 
• 126423-65-2 (S)-2-((3aS,4S,6S,7aS)-6-Hydroxy-2,2-dimethyl-hexahydro-benzo[1,3]dioxol-4-yl)-N-methoxy-N-methyl-2-p-tolylmethanesulfonylamino-acetamide 
• 126423-72-1 Acetic acid (1S,2S)-2-((3aS,4S,7aS)-2,2-dimethyl-6-oxo-hexahydro-benzo[1,3]dioxol-4-yl)-1-methyl-2-p-tolylmethanesulfonylamino-ethyl ester 
• 126423-68-5 N-{(S)-1-[(3aS,4S,6S,7aS)-6-(tert-Butyl-dimethyl-silanyloxy)-2,2-dimethyl-hexahydro-benzo[1,3]dioxol-4-yl]-2-oxo-ethyl}-C-p-tolyl-methanesulfonamide 

Relevant academic research and scientific papers

Optimization of P2Y12 Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties

P2Y12 antagonists are widely used as antiplatelet agents for the prevention and treatment of arterial thrombosis. Based on the scaffold of a known P2Y12 antagonist AZD1283, a series of novel bicyclic pyridine derivatives were designed and synthesized. The cyclization of the ester substituent on the pyridine ring to the ortho-methyl group led to lactone analogues of AZD1283 that showed significantly enhanced metabolic stability in subsequent structure-pharmacokinetic relationship studies. The metabolic stability was further enhanced by adding a 4-methyl substituent to the piperidinyl moiety. Compound 58l displayed potent inhibition of platelet aggregation in vitro as well as antithrombotic efficacy in a rat ferric chloride model. Moreover, 58l showed a safety profile that was superior to what was observed for clopidogrel in a rat tail-bleeding model. These results support the further evaluation of compound 58l as a promising drug candidate.

Design, synthesis and evaluation of sulfonylurea-containing 4-phenoxyquinolines as highly selective c-Met kinase inhibitors

Deregulation of receptor tyrosine kinase c-Met has been reported in human cancers and is considered as an attractive target for small molecule drug discovery. In this study, a series of 4-phenoxyquinoline derivatives bearing sulfonylurea moiety were designed, synthesized and evaluated for their c-Met kinase inhibition and cytotoxicity against tested four cell lines in vitro. The pharmacological data indicated that most of the tested compounds showed moderate to significant potency as compared with foretinib, with the most promising compound 13x (c-Met kinase IC50 = 1.98 nM) demonstrated relatively good selectivity versus 10 other tyrosine kinases and remarkable cytotoxicities against HT460, MKN-45, HT-29 and MDA-MB-231 with IC50 values of 0.055 μM, 0.064 μM, 0.16 μM and 0.49 μM, respectively. The preliminary structure activity relationships indicated that a sulfonylurea moiety as linker as well as mono-EGWs (such as R1 = 4-F) on the terminal phenyl rings contributed to the antitumor activity.

NEW PYRIDINE ANALOGUES

The present invention relates to certain new pyridin analogues of Formula (I) Chemical formula should be inserted here. Please see paper copy Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.